(Q36627275)

15 August 2017

1 reference

title

Panitumumab in colon cancer: a review and summary of ongoing trials (English)

1 reference

15 August 2017

1 reference

Zev Wainberg

1

1 reference

15 August 2017

J Randolph Hecht

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Biological Therapy

15 August 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1229-1235

1 reference

15 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Adjuvant therapy of stage II and III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1229

10.1517/14712598.6.11.1229

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference